{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:44:01Z","timestamp":1791233041268,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG24451"],"award-info":[{"award-number":["IG24451"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007706","name":"Ministero dello Sviluppo Economico","doi-asserted-by":"publisher","award":["BIOMIND"],"award-info":[{"award-number":["BIOMIND"]}],"id":[{"id":"10.13039\/501100007706","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007706","name":"Ministero dello Sviluppo Economico","doi-asserted-by":"publisher","award":["SPID"],"award-info":[{"award-number":["SPID"]}],"id":[{"id":"10.13039\/501100007706","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["MUR-PNRR M4C2I1.3 PE6 project PE00000019"],"award-info":[{"award-number":["MUR-PNRR M4C2I1.3 PE6 project PE00000019"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNC-E3-2022-23683266"],"award-info":[{"award-number":["PNC-E3-2022-23683266"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente 2022-2024"],"award-info":[{"award-number":["Ricerca Corrente 2022-2024"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019470","name":"Lazio Innova","doi-asserted-by":"publisher","award":["A0613-2023-078139"],"award-info":[{"award-number":["A0613-2023-078139"]}],"id":[{"id":"10.13039\/100019470","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06941-1","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T13:45:33Z","timestamp":1755092733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Development of an innovative duplex digital PCR assay for circulating MiRNA ratio quantification in metastatic melanoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Alex","family":"De Gregorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sacconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Mandoj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"De Pascale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaelena","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Meinardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Guerresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Terrenato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cigliana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"Russillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Ferraresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Fanciulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Blandino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Ciliberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Fattore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"issue":"2","key":"6941_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ccell.2024.11.009","volume":"43","author":"C Alix-Panabi\u00e8res","year":"2025","unstructured":"Alix-Panabi\u00e8res C, Pantel K. Advances in liquid biopsy: from exploration to practical application. Cancer Cell. 2025;43(2):161\u20135.","journal-title":"Cancer Cell"},{"issue":"1","key":"6941_CR2","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, et al. Liquid biopsy in cancer current: status, challenges and future prospects. Signal Transduct Target Ther. 2024;9(1):336.","journal-title":"Signal Transduct Target Ther"},{"key":"6941_CR3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3791","author":"A Monette","year":"2025","unstructured":"Monette A, Aguilar-Mahecha A, Altinmakas E, Angelos MG, Assad N, Batist G, et al. The society for immunotherapy of cancer perspective on liquid biopsy and radiomics based technologies for immuno-oncology biomarker discovery and application. Clin Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3791.","journal-title":"Clin Cancer Res"},{"key":"6941_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071377","author":"TA Allen","year":"2024","unstructured":"Allen TA. The role of circulating tumor cells as a liquid biopsy for cancer: advances, biology, technical challenges, and clinical relevance. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16071377.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6941_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-025-00876-y","volume":"9","author":"A Bartolomucci","year":"2025","unstructured":"Bartolomucci A, Nobrega M, Ferrier T, Dickinson K, Kaorey N, Nadeau A, et al. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. NPJ Precis Oncol. 2025;9(1):1\u201319. https:\/\/doi.org\/10.1038\/s41698-025-00876-y.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"6941_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01671-0","volume":"21","author":"Q-F Han","year":"2022","unstructured":"Han Q-F, Li W-J, Hu K-S, Gao J, Zhai W-L, Yang J-H, et al. Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer. Mol Cancer. 2022;21(1): 207.","journal-title":"Mol Cancer"},{"issue":"1","key":"6941_CR7","first-page":"114","volume":"25","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhang H, Li H, Xiong J, Wang J, Huang Y. Application of tumor-educated platelets as new fluid biopsy markers in various tumors. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2023;25(1):114\u201325.","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"issue":"1","key":"6941_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41416-023-02488-4","volume":"130","author":"W Shi","year":"2024","unstructured":"Shi W, Wartmann T, Accuffi S, Al-Madhi S, Perrakis A, Kahlert C, et al. Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer. Br J Cancer. 2024;130(1):125\u201334.","journal-title":"Br J Cancer"},{"issue":"1","key":"6941_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02298-7","volume":"24","author":"SY Lim","year":"2025","unstructured":"Lim SY, Boyd SC, Diefenbach RJ, Rizos H. Circulating MicroRNAs: functional biomarkers for melanoma prognosis and treatment. Mol Cancer. 2025;24(1): 99.","journal-title":"Mol Cancer"},{"issue":"7","key":"6941_CR10","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3390\/genes14071375","volume":"14","author":"A Chakrabortty","year":"2023","unstructured":"Chakrabortty A, Patton DJ, Smith BF, Agarwal P. miRNAs: potential as biomarkers and therapeutic targets for cancer. Genes (Basel). 2023;14(7):1375.","journal-title":"Genes (Basel)."},{"issue":"1","key":"6941_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/CBM-210223","volume":"35","author":"S Takizawa","year":"2022","unstructured":"Takizawa S, Matsuzaki J, Ochiya T. Circulating micrornas: challenges with their use as liquid biopsy biomarkers. Cancer Biomark. 2022;35(1):1\u20139.","journal-title":"Cancer Biomark"},{"issue":"1","key":"6941_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-020-05190-3","volume":"13","author":"PDR Cirillo","year":"2020","unstructured":"Cirillo PDR, Margiotti K, Mesoraca A, Giorlandino C. Quantification of circulating microRNAs by droplet digital PCR for cancer detection. BMC Res Notes. 2020;13(1):1\u20136. https:\/\/doi.org\/10.1186\/s13104-020-05190-3.","journal-title":"BMC Res Notes"},{"key":"6941_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093141","author":"N Coccaro","year":"2020","unstructured":"Coccaro N, Tota G, Anelli L, Zagaria A, Specchia G, Albano F. Digital PCR: a reliable tool for analyzing and monitoring hematologic malignancies. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21093141.","journal-title":"Int J Mol Sci"},{"key":"6941_CR14","doi-asserted-by":"publisher","first-page":"343440","DOI":"10.1016\/j.aca.2024.343440","volume":"1335","author":"F Busato","year":"2025","unstructured":"Busato F, Ursuegui S, Deleuze JF, Tost J. Multiplex digital PCR for the simultaneous quantification of a miRNA panel. Anal Chim Acta. 2025;1335:343440. https:\/\/doi.org\/10.1016\/j.aca.2024.343440.","journal-title":"Anal Chim Acta"},{"key":"6941_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9040063","author":"K Saginala","year":"2021","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. Epidemiology of melanoma. Med Sci. 2021. https:\/\/doi.org\/10.3390\/medsci9040063.","journal-title":"Med Sci"},{"issue":"6","key":"6941_CR16","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41591-019-0448-9","volume":"25","author":"PA Ascierto","year":"2019","unstructured":"Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med. 2019;25(6):941\u20136.","journal-title":"Nat Med"},{"key":"6941_CR17","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fcell.2020.00672","volume":"8","author":"Q Lei","year":"2020","unstructured":"Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors. Front Cell Dev Biol. 2020;8:672.","journal-title":"Front Cell Dev Biol"},{"issue":"17","key":"6941_CR18","doi-asserted-by":"publisher","first-page":"7420","DOI":"10.7150\/thno.77761","volume":"12","author":"CF Ruggiero","year":"2022","unstructured":"Ruggiero CF, Fattore L, Terrenato I, Sperati F, Salvati V, Madonna G, et al. Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma. Theranostics. 2022;12(17):7420\u201330.","journal-title":"Theranostics"},{"issue":"1","key":"6941_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s13046-023-02878-9","volume":"42","author":"V Castaldo","year":"2023","unstructured":"Castaldo V, Minopoli M, Di Modugno F, Sacconi A, Liguoro D, Frigerio R, et al. Upregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestin. J Exp Clin Cancer Res. 2023;42(1):317.","journal-title":"J Exp Clin Cancer Res"},{"issue":"34","key":"6941_CR20","doi-asserted-by":"publisher","first-page":"E5005","DOI":"10.1073\/pnas.1607753113","volume":"113","author":"L Fattore","year":"2016","unstructured":"Fattore L, Mancini R, Acunzo M, Romano G, Lagan\u00e0 A, Pisanu ME, et al. MiR-579-3p controls melanoma progression and resistance to target therapy. Proc Natl Acad Sci U S A. 2016;113(34):E5005\u201313.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6941_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0570-5","volume":"13","author":"BC Melnik","year":"2015","unstructured":"Melnik BC. MiR-21: an environmental driver of malignant melanoma? J Transl Med. 2015;13: 202.","journal-title":"J Transl Med"},{"issue":"1","key":"6941_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12935-023-02972-0","volume":"23","author":"P Sameti","year":"2023","unstructured":"Sameti P, Tohidast M, Amini M, Bahojb Mahdavi SZ, Najafi S, Mokhtarzadeh A. The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target. Cancer Cell Int. 2023;23(1):134.","journal-title":"Cancer Cell Int"},{"key":"6941_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030326","author":"A Gajos-Michniewicz","year":"2019","unstructured":"Gajos-Michniewicz A, Czyz M. Role of miRNAs in melanoma metastasis. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11030326.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"6941_CR24","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ebiom.2015.05.011","volume":"2","author":"MS Stark","year":"2015","unstructured":"Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, Tang YH, et al. The prognostic and predictive value of melanoma-related micrornas using tissue and serum: a microRNA expression analysis. EBioMedicine. 2015;2(7):671\u201380.","journal-title":"EBioMedicine"},{"issue":"6","key":"6941_CR25","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/bjc.2017.477","volume":"118","author":"R Van Laar","year":"2018","unstructured":"Van Laar R, Lincoln M, Van Laar B. Development and validation of a plasma-based melanoma biomarker suitable for clinical use. Br J Cancer. 2018;118(6):857\u201366.","journal-title":"Br J Cancer"},{"issue":"3","key":"6941_CR26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/bjd\/ljad137","volume":"189","author":"R Van Laar","year":"2023","unstructured":"Van Laar R, Latif B, King S, Love C, Taubenheim N, Kalansooriya E, et al. Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma. Br J Dermatol. 2023;189(3):292\u2013301.","journal-title":"Br J Dermatol"},{"key":"6941_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153706","author":"L Levati","year":"2022","unstructured":"Levati L, Bassi C, Mastroeni S, Lupini L, Antonini Cappellini GC, Bonmassar L, et al. Circulating miR-1246 and miR-485-3p as promising biomarkers of clinical response and outcome in melanoma patients treated with targeted therapy. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14153706.","journal-title":"Cancers (Basel)"},{"key":"6941_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s41936-024-00360-2","author":"MT Quang","year":"2024","unstructured":"Quang MT, Nguyen MN. The potential of microRNAs in cancer diagnostic and therapeutic strategies: a narrative review. J Basic Appl Zool. 2024. https:\/\/doi.org\/10.1186\/s41936-024-00360-2.","journal-title":"J Basic Appl Zool"},{"issue":"8","key":"6941_CR29","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1200\/JCO.2013.50.4357","volume":"32","author":"G Sozzi","year":"2014","unstructured":"Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(8):768\u201373.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6941_CR30","volume":"46","author":"M Boeri","year":"2024","unstructured":"Boeri M, Sabia F, Ledda RE, Balbi M, Suatoni P, Segale M, et al. Blood microRNA testing in participants with suspicious low-dose CT findings: follow-up of the BioMILD lung cancer screening trial. Lancet Reg Health. 2024;46: 101070.","journal-title":"Lancet Reg Health"},{"issue":"9","key":"6941_CR31","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/cncy.22829","volume":"132","author":"T Verma","year":"2024","unstructured":"Verma T, Marshall C, Dantey KE, Thompson DV, Banizs A, Finkelstein SD, et al. The role of the ThyGeNEXT oncogene panel used in combination with the expanded miRNA panel ThyraMIRv2 in indeterminate thyroid nodules: a large, blinded, real-world, observational study. Cancer Cytopathol. 2024;132(9):556\u201363.","journal-title":"Cancer Cytopathol"},{"issue":"2","key":"6941_CR32","doi-asserted-by":"publisher","first-page":"20501","DOI":"10.11613\/BM.2024.020501","volume":"34","author":"M Zendjabil","year":"2024","unstructured":"Zendjabil M. Preanalytical, analytical and postanalytical considerations in circulating microRNAs measurement. Biochem medica. 2024;34(2):20501.","journal-title":"Biochem medica"},{"key":"6941_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051166","author":"A Babayan","year":"2020","unstructured":"Babayan A, Neumann MHD, Herdean A, Shaffer JM, Janning M, Kobus F, et al. Multicenter evaluation of independent high-throughput and RT-qPCR technologies for the development of analytical workflows for circulating miRNA analysis. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12051166.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6941_CR34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1515\/cclm-2023-0131","volume":"62","author":"SR Greytak","year":"2024","unstructured":"Greytak SR, Engel KB, Hoon DSB, Elias KM, Lockwood CM, Guan P, et al. Evidence-based procedures to improve the reliability of circulating miRNA biomarker assays. Clin Chem Lab Med. 2024;62(1):60\u20136.","journal-title":"Clin Chem Lab Med"},{"key":"6941_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063403","author":"K Felekkis","year":"2024","unstructured":"Felekkis K, Papaneophytou C. The circulating biomarkers league: combining miRNAs with cell-free DNAs and proteins. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25063403.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6941_CR36","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3390\/ijms26031219","volume":"26","author":"G Gattuso","year":"2025","unstructured":"Gattuso G, Longo F, Spoto G, Ricci D, Lavoro A, Candido S, et al. Diagnostic and prognostic significance of a four-miRNA signature in colorectal cancer. Int J Mol Sci. 2025;26(3):1219.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"6941_CR37","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3892\/ijo.2012.1647","volume":"41","author":"A Allegra","year":"2012","unstructured":"Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012;41(6):1897\u2013912.","journal-title":"Int J Oncol"},{"issue":"6","key":"6941_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020769","volume":"6","author":"R Duttagupta","year":"2011","unstructured":"Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS ONE. 2011;6(6): e20769.","journal-title":"PLoS ONE"},{"issue":"3","key":"6941_CR39","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/1940-6207.CAPR-11-0370","volume":"5","author":"CC Pritchard","year":"2012","unstructured":"Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila). 2012;5(3):492\u20137.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"8","key":"6941_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237023","volume":"15","author":"Z Shen","year":"2020","unstructured":"Shen Z, Sun J, Shao J, Xu J. Ultraviolet B irradiation enhances the secretion of exosomes by human primary melanocytes and changes their exosomal miRNA profile. PLoS ONE. 2020;15(8): e0237023.","journal-title":"PLoS ONE"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06941-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06941-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06941-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:51:31Z","timestamp":1757422291000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06941-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6941"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06941-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committees of both participating institutions: the IRCCS \u201cG. Pascale Foundation\u201d (Approval Numbers DSC\/1504, June 11, 2014 and DSC\/2893, April 11, 2015) and the IRCCS Regina Elena National Cancer Institute-IFO (Approval Number 8393, July 23, 2017), in accordance with the Declaration of Helsinki. Inclusion criteria specified patients aged\u2009\u2265\u200918 years with histologically confirmed, locally advanced or metastatic melanoma (Stage IIIB-IIIC or IV according to the American Joint Committee on Cancer, 7th Edition), eligible for MAPK-targeted therapy, and capable of providing informed consent. Samples from healthy donors were collected with the approval of the IRCCS Regina Elena National Cancer Institute (Rome, Italy) institutional ethics committee (Approval Number 7182, May 24, 2019). Written informed consent was obtained from all participants before inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors agreed for publication of this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors declare no conflict of interest with the exceptions of P.A.A. P.A.A. has\/had a consultant\/advisory role for Bristol MyersSquibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTX, Replimmune. He also received research funding from Bristol Myers Squibb, Roche-Genentech, Pfizer, Sanofi. Travel support by Pfizer. The funders of this study had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"904"}}